Form 4: Madrigal Pharmaceuticals: Insider Stock and Option Grants

Baker Bros. Advisors LP and affiliated entities report grants of restricted stock units and non-qualified stock options to directors Julian C. Baker and Dr. Raymond Cheong.

Summary

• Baker Bros. Advisors LP and related entities have filed a Form 4 detailing transactions related to Madrigal Pharmaceuticals, Inc. (MDGL).
• The filing reports the grant of 454 restricted stock units (RSUs) to Julian C. Baker and Dr. Raymond Cheong on June 17, 2026. These RSUs vest on June 17, 2027, or the 2027 annual meeting, whichever is earlier.
• Additionally, 766 non-qualified stock options with an exercise price of $499.86 were granted to Julian C. Baker and Dr. Raymond Cheong on June 17, 2026. These options vest on June 17, 2027, or the 2027 annual meeting, and expire 10 years from the grant date.
• These grants are made under the Issuer's 2026 Stock Plan.
• The reporting persons, including Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, 667, L.P., and Baker Brothers Life Sciences LP, disclaim beneficial ownership except to the extent of their pecuniary interest.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the securities due to their ownership interests in the general partners and funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine equity grants to directors and does not contain financial performance or strategic updates.

Positives

• Grant of equity awards (RSUs and stock options) to key personnel, indicating a commitment to long-term incentives and retention.
• The stock options have a strike price of $499.86, suggesting a valuation of the company at that level or higher.
• Vesting schedules tied to service and annual meetings align incentives with company performance and governance.

Negatives

• The filing does not contain financial performance data, making it difficult to assess the company's current financial health.
• Details on the specific reasons for the grants beyond standard compensation for director service are not provided.

Risks

• The value of the RSUs and stock options is subject to the future performance of Madrigal Pharmaceuticals' stock price.
• Vesting is contingent on continuous service, meaning departure from the company before vesting would result in forfeiture of these awards.
• The indirect nature of beneficial ownership reported by Baker Bros. entities introduces complexity in assessing ultimate control and interest.

Future Outlook

The future outlook for the RSUs and stock options is tied to the company's stock performance and the vesting schedules, with options expiring 10 years from the grant date.

Management Comments

• Julian C. Baker and Dr. Raymond Cheong are directors of Madrigal Pharmaceuticals, Inc.
• By virtue of their representation on the board, reporting persons other than Julian C. Baker are deemed directors by deputization.
• The reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the pharmaceutical and biotechnology sectors to align executive and director interests with shareholder value.

Related Party Transactions

• Grants of RSUs and stock options to directors Julian C. Baker and Dr. Raymond Cheong, who are associated with Baker Bros. Advisors LP and its affiliates.

Stakeholder Impact

• Shareholders: The grants represent potential future dilution and an incentive for directors to act in the company's best interest.
• Directors (Julian C. Baker, Dr. Raymond Cheong): Receive equity awards as compensation for their service.
• Baker Bros. Entities: May have indirect pecuniary interests in the awarded securities.

Next Steps

• Vesting of RSUs and stock options on June 17, 2027, or the 2027 annual meeting.
• Expiration of stock options 10 years from the grant date (June 17, 2036).

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Awards, Madrigal Pharmaceuticals, MDGL, Baker Bros. Advisors, Director Compensation, SEC Filing